ZURICH - Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for gubernatorial


compliancehelp your classification comply with multinational regulations! learn morewww.dataflux.comgb pharmaa full service cro: ricerca clinica farmacovigilanza filings in the United States, Europe and Switzerlan...

More: - Read More